• 1
    Hirschowitz B, Mohnen J, Shaw S. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. Aliment Pharmacol Ther 1996; 10: 497506.
  • 2
    Hirschowitz BI, Mohnen J, Shaw S. A prospective long-term study of lansoprazole for treatment of Zollinger–Ellison syndrome. Aliment Pharmacol Ther 1996; 10: 50722.
  • 3
    Kirkpatrick PM & Hirschowitz BI. Duodenal ulcer with unexplained marked basal gastric acid hypersecretion. Gastroenterology 1980; 79: 410.
  • 4
    Annibale B, Aprile MR, Ferrara G, et al. Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases. Aliment Pharmacol Ther 1998; 12: 77988.DOI: 10.1046/j.1365-2036.1998.00365.x
  • 5
    Hirschowitz BI. Clinical course of nonsurgically treated Zollinger–Ellison Syndrome. In: Mignon M, Jensen RT, eds. Endocrine Tumours of the Pancreas – Recent Advances, Vol. 23 of Frontiers in Gastrointestinal Research series. Basel: S. Karger AG, 1994, pp. 360–71.
  • 6
    Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger–Ellison syndrome. N Eng J Med 1999; 341: 63544.
  • 7
    Maton PN, Frucht H, Vinayek R, Wank SA, Gardner JD, Jensen RT. Medical management of patients with Zollinger–Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 1988; 94: 294294.
  • 8
    Jensen RT & Gardner JD. Zollinger–Ellison syndrome: clinical presentation, pathology, diagnosis, and treatment. In: Zakim D, Dannenberg AJ, eds. Peptic Ulcer Disease and Other Related Disorders. Armonk, New York: Academic Research Association, 1991: 177–211.
  • 9
    Bell NJV, Burgett D, Howden C, et al. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 52(Suppl. 1): 5967.
  • 10
    Burget D, Chiverton SG, Hunt R. Is there an optimal degree of acid suppression for healing duodenal ulcers? Gastroenterology 1990; 99: 334551.
  • 11
    Vallot T, Mignon M, Azure R, Bonfils S. Evaluation of antisecretory drug therapy of Zollinger–Ellison Syndrome (ZES). Dig Dis Sci 1983; 28: 57784.
  • 12
    Paul G, Ramdani A, Mignon M, et al. Comparative efficacy of lansoprazole and omeprazole on the intragastric pH over a period of 24 hr and on the basal acid output in 9 patients with Zollinger–Ellison (Fr). Gastroenterol Clin Biol 1994; 18: 695701.
  • 13
    Maton PN, Gardner JD, Jensen RT. Diagnosis and management of Zollinger–Ellison syndrome. Endocrinol Metab Clin North Am 1989; 18(2): 51943.
  • 14
    Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger–Ellison syndrome are too high. Gastroenterology 1992; 103: 1496508.
  • 15
    Met DC, Strader DB, Orbuch N, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger–Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7(597–610): 1616.
  • 16
    Jensen RT, Metz DC, Koviack PD, Feigenbaum KM. Prospective study of the long-term efficacy and safety of lansoprazole in patients with Zollinger–Ellison syndrome. Aliment Pharmacol Ther 1993; 7(Suppl.): 4150.
  • 17
    Yeomans ND & Dent J. Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion. Aliment Pharmacol Ther 2000; 14: 26771.DOI: 10.1046/j.1365-2036.2000.00750.x
  • 18
    Hirschowitz BI & Groarke J. Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls. Dig Dis Sci 1993; 38: 187484.
  • 19
    Hirschowitz BI & Haber MM. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger–Ellison syndrome acid hypersecretors treated long-term with omeprazole. Aliment Pharmacol Ther 2001; 15: 86103.
  • 20
    Miller LS, Vinayek R, Frucht H, Gardner JD, Jensen RT, Maton PN. Reflux esophagitis in patients with Zollinger–Ellison syndrome. Gastroenterology 1990; 98: 3416.
  • 21
    Blair AJ 3d, Feldman M, Barnett C, Walsh JH, Richardson CT. Detailed comparison of basal and food-stimulated gastric acid secretion rates and serum gastrin concentrations in duodenal ulcer patients and normal subjects. J Clin Invest 1987; 79: 5827.
  • 22
    Hirschowitz BI, Johnson LR, Worthington J, Mohnen J. Esophagitis in ZE and non-ZE patients with acid hypersecretion (BAO > 15 mEq/h) treated prospectively for up to 10 yr with lansoprazole. Gastroenterology 2000; 118: A17A17 (Abstract).
  • 23
    Hirschowitz BI, Mohnen J, Worthington J. Clinical outcome with long-term (up to 10 yr) lansoprazole treatment of acid hypersecretors (BAO > 15 MM/h) (ZE and non-ZE) — role of acid, pepsin and H. pylori. Gastroenterology 2000; 18: A1084A1084(Abstract).
  • 24
    Hirschowitz BI. Pepsin and the esophagus. Yale J Biol Med 1999; 72: 1343.
  • 25
    Griffith JL, Cummings OW, Hirschowitz BI. Development of sustained achlorhydria in a patient with Zollinger–Ellison syndrome treated with omeprazole. Gastroenterology 1991; 101: 2426.
  • 26
    Hirschowitz BI & Lanas A. Intractable upper GI ulceration due to ASA in patients who have had surgery for peptic ulcer. Gastroenterology 1998; 114: 19.
  • 27
    Zimmer T. Brief report: a duodenal gastrinoma in a patient with diarrhea and normal serum gastrin concentrations. N Engl J Med 1995; 333(10): 6346.
  • 28
    Jais P. Normal serum gastrin concentration in gastrinoma. Lancet 1995; 346(8987): 14212.
  • 29
    Malegelada RJ, Davis CS, O'Fallon WM, Go VL. Laboratory diagnosi of gastrinoma. Mayo Clin Proc 1982; 57: 2118.
  • 30
    Klinkenberg-Knol EC, Nelis F, Dent J, et al. and long-term study group. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 6619.
  • 31
    Sagar M. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 2000; 119(3): 6706.
  • 32
    Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129(12): 102730.
  • 33
    Lanas AI, Blas JM, Ortego J, et al. Adaptations of esophageal mucosa to acid and pepsin-induced damage: role of nitrous oxide and epidermal growth factors. Dig Dis Sci 1997; 42: 100312.
  • 34
    Barradell LB, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44(2): 2264.
  • 35
    Hersey SJ. Cellular basis of pepsinogen secretion. In: Schultz SG, Forte JG, eds. Handbook of Physiology, III, Section 6: Alimentary Tract. Bethesda, MD: American Physiological Society, 1989: 267–278.